Adventris Pharmaceuticals
Adventris develops cancer vaccines to prevent and treat cancer deaths.
Founded
2022Accelerator
Adventris develops cancer vaccines to prevent and treat cancer deaths.
Adventris Pharmaceuticals, founded with a mission to revolutionize cancer treatment, focuses on developing cancer vaccines that harness the body's immune system to recognize and eliminate cancer cells. Their innovative approach targets specific mutations responsible for the majority of cancer deaths, aiming to significantly reduce cancer mortality rates. The company's core vision is to transform cancer care through advanced immunotherapy solutions, making effective cancer prevention and treatment accessible to all.
Notable figures associated with Adventris include leading scientists and industry experts in oncology and immunotherapy. The company has attracted significant attention from investors in the biotechnology sector, reflecting confidence in its groundbreaking approach. Key achievements include successful preclinical trials demonstrating the efficacy of their vaccines in targeting cancer mutations. Adventris's impact lies in its potential to dramatically alter the landscape of cancer treatment, offering hope for a future where cancer can be effectively managed or eradicated.
Companies similar to Adventris Pharmaceuticals include Adventris Pharmaceuticals, Velorum Therapeutics, Eris Biotech and Serinus Biosciences.
Adventris Pharmaceuticals was founded in 2022.
Adventris Pharmaceuticals' most recent funding round was for $500k (USD) in January 2023.
As of Jan 1, 2023, Adventris Pharmaceuticals has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
Adventris Pharmaceuticals has 7 employees as of Aug 23, 2023.
Serinus Biosciences
serinus.bio
